Detalles de la búsqueda
1.
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
PLoS One
; 13(8): e0202709, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110398
2.
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
PLoS One
; 13(6): e0198389, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29856824
3.
MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.
Oncotarget
; 6(1): 288-304, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25481872
4.
AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.
Neoplasia
; 15(9): 1009-17, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24027426
5.
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
J Clin Endocrinol Metab
; 98(5): E820-8, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23533230
6.
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
J Clin Invest
; 120(8): 2715-30, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20644256
7.
Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.
Clin Cancer Res
; 15(24): 7634-7641, 2009 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19996218
Resultados
1 -
7
de 7
1
Próxima >
>>